ERBB2 and breast cancer: Eleven patients had no treatment or follow-up data, 3 had another malignancy in the 5 years preceding the 21-gene assay (1 ovarian cancer, 1 HER2 + BC, and 1 rectal cancer and BC), 2 were HER2 + , 1 was metastatic at the time of testing, and 1 had 2 tests performed at the same time of which one yielded RS result >30 (Fig. 1).